Navigation Links
OncologyRx Care Advantage™ Chosen to Fill Prescriptions for Jakafi™ (ruxolitinib)

THE WOODLANDS, Texas, Nov. 22, 2011 /PRNewswire/ -- OncologyRx Care Advantage, McKesson Specialty Health's oral oncology products specialty pharmacy, has been selected by Incyte Corporation as one of only a limited number of  pharmacies across the U.S. authorized to fill prescriptions for Jakafi (ruxolitinib), an oral prescription medicine used to treat Myelofibrosis (MF) patients.  


"OncologyRx Care Advantage has a strong focus and commitment to oncologists and cancer patients," said Roger W. Anderson, Dr.P.H., chief pharmacy officer, McKesson Specialty Health. "We are excited that Care Advantage was chosen as one of a limited number of pharmacies to dispense Jakafi. Our oncology expertise and extensive patient care support can lead to better outcomes by helping Myelofibrosis patients better understand their disease and comply with their treatment."

Myelofibrosis is a disorder of the bone marrow, in which the marrow is replaced by scar (fibrous) tissue.  Jakafi received approval from the Food and Drug Administration (FDA) on Nov. 16, and is the only medicine approved by the FDA to treat MF. Until Jakafi's approval, there were few options for patients with MF; some patients have been treated with medicines approved by the FDA to treat other diseases, with limited success.

Care Advantage provides patients with convenient home delivery of oral therapies and the additional support necessary for safe and supervised use of these oral medications. The pharmacy's team of specialists, including pharmacists, oncology certified nurses, and patient access coordinators, provides critical patient support that includes proactive monitoring of compliance, supporting adherence through education, helping with side effect management, and seeking access for co-pay assistance through various cancer foundations.

In addition to Care Advantage, only a select few specialty pharmacies are authorized to dispense Jakafi to patients.

"Care Advantage provides vital services and resources to patients," said Dr. Anderson. "Being chosen to provide this new drug to patients further enhances our ability to support both oncologists and patients battling Myelofibrosis."

About McKesson Specialty Health
McKesson Specialty Health, a division of McKesson Corporation, empowers the community patient care delivery system to advance the science, technology and quality of care. Through innovative clinical, research, business and operational solutions, facilitated by integrated technology systems, we help improve the financial health of our customers and help them provide quality care for patients. For more information, visit

About McKesson
McKesson Corporation, currently ranked 15th on the FORTUNE 500, is a healthcare services and information technology company dedicated to making the business of healthcare run better. We partner with payers, hospitals, physician offices, pharmacies, pharmaceutical companies and others across the spectrum of care to build healthier organizations that deliver better care to patients in every setting. McKesson helps its customers improve their financial, operational, and clinical performance with solutions that include pharmaceutical and medical-surgical supply management, healthcare information technology, and business and clinical services. For more information, visit

SOURCE McKesson Specialty Health
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alabama Selects Thomson Reuters HIE Advantage™ for Statewide Health Information Exchange
2. Syndicom SpineConnect Web Platform Chosen for Applied Spines Leg and Back Pain Clinical Trial of Its Stabilimax NZ(R) Dynamic Spine Stabilization System
3. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
4. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
5. Fort Worth Surgeon Chosen as Investigator in Clinical Trial for Weight-Loss Device
6. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
7. Oramed Pharmaceuticals was Chosen to Present Results of a GLP-1 Analog Oral Administration Study at the Diabetes Technology Societys Ninth Annual Meeting (November 5-7, 2009; San Francisco, CA)
8. Simmons Firms Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer
9. Oridion Microstream(R) Technology Chosen by the Bavarian Red Cross for Improved Patient Safety
10. ECRI Institute PSO Chosen by Tennessee Hospital Association for Patient Safety Services
11. Smith & Nephews Exclusive OXINIUM™ Material for Hip Replacement Implants Chosen for Premium Reimbursement in Japanese Market
Post Your Comments:
(Date:12/1/2015)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel ... the company will present at the LD Micro Main Event. ... Sunset Boulevard Hotel in Los Angeles, CA. ... present on Thursday, December 3, at 9:00 am Pacific time ... at least 10 minutes prior to the start of the ...
(Date:12/1/2015)... Dec. 1, 2015   MabVax Therapeutics Holdings, Inc ... announces it has filed an Investigational New Drug Application ... for the Company,s lead fully human antibody product HuMab ... MabVax plans to initiate the Phase I clinical trial ... --> The planned Phase I trial will ...
(Date:12/1/2015)... 2015   Craneware, Inc ., the healthcare ... announced the company will showcase a new version ... solution at the American Society for Health-System ... The new features are focused on simplifying and ... managing enterprise-wide pharmacy charges to ensure compliance and ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... Wayland, MA (PRWEB) , ... December 01, 2015 , ... ... adults has a tattoo — a number even greater among Millennials (a whopping one ... there are more and more people who are dissatisfied with their ink. In fact, ...
(Date:12/1/2015)... Libertyville, IL (PRWEB) , ... December 01, 2015 ... ... catheters, keeping their independence is everything. That is why Hollister Incorporated has launched ... excited to offer this next product in the VaPro touch free catheter portfolio,” ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of ... latest addition to the devices for sale in the United States. Clarity is ... long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to own ...
(Date:12/1/2015)... , ... December 01, 2015 , ... With FCPX ... and with full control over customization, the possibilities are truly endless, all with a ... randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, all ...
Breaking Medicine News(10 mins):